News | November 10, 2022
AGC to establish Life Science Company in 2023
The Group will continue to make proactive investments of its management resources in the life science business
The Group will continue to make proactive investments of its management resources in the life science business
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The new facility is scheduled to start operation in the first half of 2024
Subscribe To Our Newsletter & Stay Updated
